18620-92-3 Usage
Heterocyclic compound
It contains both pyrrolo and pyrimidine rings, which are heterocyclic, meaning they have atoms other than carbon in their structure.
Pyrrolo and pyrimidine rings
The presence of these two specific rings in the structure gives the compound its unique properties and potential pharmaceutical applications.
Anti-cancer activity
1H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine (9CI) has been studied for its potential to inhibit cancer cell growth and proliferation.
Anti-inflammatory activity
The compound has shown promise in reducing inflammation, which is a key factor in many diseases and conditions.
Pharmaceutical drug development
1H-Pyrrolo[2,3-d]pyrimidine-2,4-diamine (9CI) has potential use in the development of new pharmaceutical drugs, particularly in the field of medicinal chemistry.
Further research needed
More studies are required to fully understand and harness the potential of this compound for medicinal applications, including its mechanisms of action, safety, and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 18620-92-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,6,2 and 0 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 18620-92:
(7*1)+(6*8)+(5*6)+(4*2)+(3*0)+(2*9)+(1*2)=113
113 % 10 = 3
So 18620-92-3 is a valid CAS Registry Number.
18620-92-3Relevant articles and documents
Mannich-type C-nucleosidations with 7-carba-purines and 4-aminopyrimidines
Han, Bo,Rajwanshi, Vivek,Nandy, Jyoti,Krishnamurthy, Ramanarayanan,Eschenmoser, Albert
, p. 744 - 750 (2007/10/03)
Regioselective Mannich-type C-nucleosidations of pyrroline derivatives 3 and 8 with 7-carba-purines and 4-aminopyrimidines occur under mild conditions to afford C(8)- and C(5)-azanucleosides, respectively.
